GlassScriptPhysician profile
Andrew Pedinoff
NPI 1033116801
$3,095.04
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.87 · 2021: $2,611 · 2022: $283 · 2023: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,349.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $339.89 | 2021-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $136.91 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $87.37 | 2021-2023 | Dupixent |
| Covis Pharma Gmbh | $61.74 | 2021-2022 | |
| Kaleo, INC. | $42.30 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $13.68 | 2021 | |
| Phadia US INC. | $13.49 | 2021 | |
| Leo Pharma INC. | $13.38 | 2022 | |
| Optinose US, INC. | $13.22 | 2021 | |
| Pharming Healthcare, INC. | $12.07 | 2021 | |
| Merck Sharp & Dohme LLC | $11.38 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pedinoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.